ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2798

Trajectories of Opioid Filling Patterns After Total Knee Replacement

Chandrasekar Gopalakrishnan 1, Jessica Franklin 2, Yinzhu Jin 3, Daniel Solomon 4, Jeffrey Katz 5, Yvonne Lee 6, Patricia Franklin 6, Joyce Lii 2, Rishi Desai 7 and Seoyoung C. Kim3, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, 3Brigham and Women’s Hospital and Harvard Medical School, Boston, 4Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 5Brigham and Women's Hospital/Harvard Medical School, Boston, 6Northwestern University Feinberg School of Medicine, Chicago, 7Brigham and Women's hospital, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: opioids and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T098: Orthopedics, Low Back Pain & Rehabilitation (2798–2803)

Session Type: ACR/ARP Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Patients undergoing total knee replacement (TKR) are at increased risk of persistent opioid use and opioid dependence. Group-based trajectory models can identify clusters of patients with clinically distinct, dynamic patterns of medication use over time. Evaluating the characteristics of patients prior to TKR within these empirically identified trajectories of prescription opioid use may be useful in identifying high-risk subgroups.

Methods: Using Medicare Parts A, B and D claims (2010-2014), we identified patients aged ≥65 years who underwent a TKR. All patients were required to be continuously enrolled in Medicare for ≥360 days prior to TKR.  To determine opioid filling patterns after TKR, patients were followed up to 360 days from the day of TKR. We modeled 12 monthly indicators of filling as both a continuous (Mean morphine equivalents (MME)/day) variable for Model 1 and a binary (Yes/No for any opioid fill) response variable for Model 2 using censored normal and logistic group-based trajectory models, respectively. Model fit was assessed using a combination of the Bayesian Information Criterion (BIC), predicted probability of group membership and number of patients assigned to each trajectory group. Baseline patient characteristics (assessed in the 360 days prior to TKR) were then tabulated by trajectory group for the final model.

Results: We identified 183,373 patients who underwent TKR during the study period. We selected the 4-group trajectory model as having the best fit for both continuous and binary indicators of filling.  Observed and predicted patterns of opioid use in each of the 4 trajectory groups identified by Model 1 are summarized in Figure 1. 78% (n=1,686) of patients assigned to Group 4 (highest opioid use group) from Model 1 were also assigned to Group 4 in Model 2 though the average MME/day in Group 4 was higher (149.8 mg vs. 43.0) in Model 1 compared to Model 2. Hence, Model 1 provided more clinically-meaningful discrimination between patients’ opioid use, and we used trajectory membership based on Model 1 to describe baseline patient characteristics (Table 1). Differences were noted in the baseline characteristics of patients assigned to group 4 compared to those assigned to Group 1 (lowest opioid use). Patients in Group 4 were more likely to be younger, female, have opioid use in the year prior to TKR, and had a greater burden of comorbidities (such as depression, anxiety disorders, back pain), more likely to have used tobacco, alcohol and used more healthcare services in general (number of ER visits, physician office visits and medications used). Patients in Group 4 were also more likely to be frail as assessed by the claims-based frailty index.

Conclusion:

Group-based trajectory models identified a subgroup of patients with high opioid use and whose baseline characteristics prior to TKR were substantially different than those in other groups. Future work could further determine the predictors of persistently high-dose opioid users after TKR and associated adverse events.


Disclosure: C. Gopalakrishnan, None; J. Franklin, None; Y. Jin, None; D. Solomon, AbbVie, 2, Abbvie, 2, Amgen, 2, AstraZeneca, 2, Corrona, 2, Genentech, 2, Janssen, 2, Lilly, 2, Pfizer, 2; J. Katz, Flexion, 2, Flexion Therapeutics, 2, Samumed, 2; Y. Lee, Cigna Corp, 1, Eli Lilly, 2, 5, Eli Lilly and Company, 2, Express Scripts, 4, Pfizer, 2; P. Franklin, None; J. Lii, None; R. Desai, Merck, 2, Vertex, 2; S. Kim, AbbVie, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Merck, 2, Pfizer, 2, research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics, 2, Roche, 2, Roche/Genentech, 2.

To cite this abstract in AMA style:

Gopalakrishnan C, Franklin J, Jin Y, Solomon D, Katz J, Lee Y, Franklin P, Lii J, Desai R, Kim S. Trajectories of Opioid Filling Patterns After Total Knee Replacement [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/trajectories-of-opioid-filling-patterns-after-total-knee-replacement/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectories-of-opioid-filling-patterns-after-total-knee-replacement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology